Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003592902 | SCV004276782 | uncertain significance | Brachyolmia-amelogenesis imperfecta syndrome | 2024-12-18 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1083 of the LTBP3 protein (p.Val1083Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with LTBP3-related conditions. ClinVar contains an entry for this variant (Variation ID: 2721029). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004369139 | SCV005038394 | uncertain significance | Inborn genetic diseases | 2024-03-13 | criteria provided, single submitter | clinical testing | The p.V1083L variant (also known as c.3247G>T), located in coding exon 24 of the LTBP3 gene, results from a G to T substitution at nucleotide position 3247. The valine at codon 1083 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004753687 | SCV005349399 | uncertain significance | LTBP3-related disorder | 2024-06-07 | no assertion criteria provided | clinical testing | The LTBP3 c.3247G>T variant is predicted to result in the amino acid substitution p.Val1083Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0068% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |